Business Description
NRX Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US6294441000
Share Class Description:
FRA:B1Q: Ordinary SharesTotal Employee Number:
29Description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.19 | |||||
Equity-to-Asset | -1.16 | |||||
Debt-to-Equity | -0.07 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -39.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.1 | |||||
3-Year EPS without NRI Growth Rate | 42.2 | |||||
3-Year FCF Growth Rate | 52.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 777.74 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.55 | |||||
9-Day RSI | 61.65 | |||||
14-Day RSI | 59.7 | |||||
3-1 Month Momentum % | 35.63 | |||||
6-1 Month Momentum % | 85.22 | |||||
12-1 Month Momentum % | 36.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.29 | |||||
Quick Ratio | 0.29 | |||||
Cash Ratio | 0.27 | |||||
Days Sales Outstanding | 30.83 | |||||
Days Payable | 1340.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -68.4 | |||||
Shareholder Yield % | -4.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 50.46 | |||||
Operating Margin % | -746.88 | |||||
Net Margin % | -1070.26 | |||||
EBITDA Margin % | -1017.4 | |||||
FCF Margin % | -652.16 | |||||
OCF Margin % | -652.16 | |||||
ROA % | -234.69 | |||||
ROIC % | -64.64 | |||||
3-Year ROIIC % | 188.31 | |||||
ROC (Joel Greenblatt) % | -3069.74 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.96 | |||||
PS Ratio | 57.44 | |||||
EV-to-EBIT | -7.87 | |||||
EV-to-EBITDA | -7.97 | |||||
EV-to-Forward-EBITDA | -12.4 | |||||
EV-to-Revenue | 81.1 | |||||
EV-to-Forward-Revenue | 7.96 | |||||
EV-to-FCF | -12.46 | |||||
Earnings Yield (Greenblatt) % | -12.71 | |||||
FCF Yield % | -7.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NRX Pharmaceuticals Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.969 | ||
| EPS (TTM) (€) | -0.944 | ||
| Beta | 1.0298 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.5 | ||
| Volatility % | 90.28 | ||
| 14-Day RSI | 59.7 | ||
| 14-Day ATR (€) | 0.160106 | ||
| 20-Day SMA (€) | 3.4685 | ||
| 12-1 Month Momentum % | 36.71 | ||
| 52-Week Range (€) | 1.37 - 4.125 | ||
| Shares Outstanding (Mil) | 42.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NRX Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NRX Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-17 08:30 | In 118 days | ||
| Third quarter earnings results for 2026 | 2026-11-17 | In 117 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 08:00 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 27 days | ||
| First quarter earnings conference call for 2026 | 2026-05-15 16:30 | 2.50 (+3.31%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.50 (+3.31%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 08:00 | 1.46 (-4.58%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 1.46 (-4.58%) | ||
| General meeting for 2025 | 2026-03-23 10:00 | 1.56 (+1.96%) | ||
| Annual report for 2025 | 2026-03-23 | 1.56 (+1.96%) |
Show
Entries
NRX Pharmaceuticals Inc Frequently Asked Questions
What is NRX Pharmaceuticals Inc(FRA:B1Q)'s stock price today?
The current price of FRA:B1Q is €3.79. The 52 week high of FRA:B1Q is €4.13 and 52 week low is €1.37.
When is next earnings date of NRX Pharmaceuticals Inc(FRA:B1Q)?
The next earnings date of NRX Pharmaceuticals Inc(FRA:B1Q) is 2026-08-19 Est..
Does NRX Pharmaceuticals Inc(FRA:B1Q) pay dividends? If so, how much?
NRX Pharmaceuticals Inc(FRA:B1Q) does not pay dividend.
Press Release
Articles on NRX Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers